ANDA 202319, held by Perrigo R&D. Lansoprazole.
As of Nov 21, 2026, ANDA 202319 (Lansoprazole), held by Perrigo R&D, was first approved by FDA on May 18, 2012, with 8 approved supplements and 0 published complete response letters.
Use
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 18, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | OTC |
| Sep 19, 2024 | Supplement 29Labeling · Standard review | Approved | None posted |
| Sep 19, 2024 | Supplement 33Labeling · Standard review | Approved | None posted |
| Sep 19, 2024 | Supplement 34Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Sep 18, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 5, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 5, 2013 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 18, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters